·SEC EDGARLow
Wilson Martin sold $128K of RCKT
Wilson Martin (General Counsel) sold 53,389 shares of ROCKET PHARMACEUTICALS, INC. (RCKT) at $2.39 ($0.13M total) on 2026-11-05.
StockNASDAQ · US · USDHealthcare · Biotechnology
$RCKT
ROCKET PHARMACEUTICALS, INC.
Rocket Pharmaceuticals develops gene therapies for rare and often fatal diseases, with a focus on inherited cardiovascular conditions and related disorders. Its programs use adeno-associated virus (AAV) and lentiviral vectors. Cardiovascular candidates include RP-A501 for Danon disease, RP-A601 for PKP2-related arrhythmogenic cardiomyopathy, and RP-A701 for BAG3 dilated cardiomyopathy. Its hematology programs include KRESLADI™, an investigational therapy for severe leukocyte adhesion deficiency-I. The company also has programs for Fanconi anemia and pyruvate kinase deficiency, though it is no longer allocating internal resources to those programs. Rocket holds global development and commercialization rights to its candidates and aims to earn money through their potential commercialization. It operates an in-house cGMP manufacturing facility in Cranbury, New Jersey, supporting clinical development and potential commercial supply. The facility is 103,720 square feet.
AlphAI earnings readSecond Quarter 2026 · AUG 10Rocket reported second-quarter net income of $123.2 million following the sale of its Priority Review Voucher, while reducing operating expenses and extending expected cash runway into the second quarter of 2028.Verdict: solidRead →
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Price · $RCKTvia TradingView
AI sentiment · 7d0 articles
No enriched coverage for $RCKT in the last 7 days.
Insider · 30dAll trades →
- Buys
- — 0 txs
- Sells
- $128K 1 txs
Wilson Martin1× · $128K
10b5-1 share of filings0%
Top stories · $RCKTMore →
·nationalmortgagenews.com
Gain on sale margins to slip in 2027, analysts warn
Rocket's Q3 earnings beat estimates, but analysts cut 2026-2028 EPS forecasts due to management's downbeat outlook. KBW reduced Rocket's target price to $16, while BTIG maintained a neutral rating. PennyMac Financial also saw lowered earnings estimates, with KBW downgrading it to market perform. BTIG kept a buy rating on PennyMac, citing attractive risk/reward.
·tradingview.com
JP Morgan maintains Rocket Companies at Neutral, raises price target to $13 from $12.50
JP Morgan kept its Neutral rating on Rocket Companies but raised its price target to $13 from $12.50, suggesting a 1.6% upside from the last close of $12.80. Recent analyst targets for the company range from $12.50 to $16.
RCKT sentiment & insider activity
Recent RCKT coverage spans financial news, earnings and regulation.
In the last 30 days, RCKT insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($128K). The most active reporter was Wilson Martin, General Counsel, with 1 filing.
What's driving RCKT
Likely mild negative read-through as an officer sells shares, but the disclosed size is small and lacks a 10b5-1 plan detail.
Analyst downgrades and lower EPS estimates suggest near‑term downside for Rocket.
Analyst upgrade suggests modest upside potential.
Guidance indicates lower mortgage volume and market size, suggesting revenue pressure for Rocket.
Guidance could improve market perception of Rocket’s rare‑disease pipeline.
AlphAI scores every news story that mentions RCKT with an AI model for sentiment and relevance, and aggregates insider trades from ROCKET PHARMACEUTICALS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $RCKT
Score
Wilson Martin sold $128K of RCKT
Wilson Martin (General Counsel) sold 53,389 shares of ROCKET PHARMACEUTICALS, INC. (RCKT) at $2.39 ($0.13M total) on 2026-11-05.
Gain on sale margins to slip in 2027, analysts warn
Rocket's Q3 earnings beat estimates, but analysts cut 2026-2028 EPS forecasts due to management's downbeat outlook. KBW reduced Rocket's target price to $16, while BTIG maintained a neutral rating. PennyMac Financial also saw lowered earnings estimates, with KBW downgrading it to market perform. BTIG kept a buy rating on PennyMac, citing attractive risk/reward.
JP Morgan maintains Rocket Companies at Neutral, raises price target to $13 from $12.50
JP Morgan kept its Neutral rating on Rocket Companies but raised its price target to $13 from $12.50, suggesting a 1.6% upside from the last close of $12.80. Recent analyst targets for the company range from $12.50 to $16.
Rocket warns 2027 mortgage market will be worse than expected
Rocket reported strong Q3 earnings with $43.6B in volume and a 254 basis point margin, but warned of a tougher mortgage market in Q4 and 2027. Executives expect refinance volume to halve, pushing it to multi-decade lows, and forecast a market below $2T. Rocket gained market share and reported $709M in net income, its second consecutive profitable quarter.
FDA draft guidance aims to speed personalized gene therapies for rare diseases (RARE:NASDAQ)
The FDA issued draft guidance to accelerate personalized gene therapies for rare diseases, offering regulatory clarity for developers. The move aims to streamline approval processes for tailored treatments, benefiting companies like Ultragenyx Pharmaceutical (RARE).
Don't bank on rate dip; servicing books win, KBW says
Mortgage rates dipped to 7.32% for 30-year fixed loans, the first decline since August, but KBW expects weak volumes due to high rates. Analysts attribute the dip to investor anxiety over tech sector profits and potential U.S. strikes post-elections. KBW remains positive on servicing-heavy companies like Rocket and Rithm.
Dan Gilbert's Rocket Gave $10M to Trump Ballroom Fund
Rocket Companies, led by Dan Gilbert, pledged $10M to a White House ballroom fund three weeks after regulators approved its $14.2B acquisition of Mr. Cooper Group. The timing has raised scrutiny, though Rocket denies any connection. The combined entity now services about 10M mortgages, or 15% of the U.S. market, according to industry reports.
StoneX maintains Buy rating on Rocket Companies, $16 price target
StoneX kept a Buy rating on Rocket Companies with a $16.00 price target, suggesting 47.7% upside from the Oct 13 close. The firm cited market share growth and resilient revenue streams as key strengths, according to their analyst note.
Rocket Companies, Inc. Stock 12‑Month Price Target Cut to $16.54, Implies 44% Upside
Rocket Companies, Inc.'s average stock price target was reduced by analysts from $16.77 to $16.54, with a range of $12.5 to $21. This implies a 44% upside from the Oct. 9 closing price. The consensus rating remains 'Buy' among 18 analysts, with 10 Buys, 8 Holds, and 0 Sells.
A Quiet Change to Credit Scoring Could Open the Door for Millions of Homebuyers
The Federal Housing Finance Agency approved VantageScore 4.0 for loans sold to Fannie Mae and Freddie Mac, potentially scoring 33 million more Americans than FICO. Rocket Mortgage adopted the new model, citing FHFA's encouragement of competition. FICO's stock dropped on the news, indicating investor awareness of potential pricing impacts.